Novo Holdings A/S
CIK 1388325 · last filed 2026-05-06
Novo Holdings A/S is a corporate insider who has filed 153 SEC Form 4 insider transactions across 44 companies since 2007. The most recent filing, for MPLT, was dated Jul 30, 2026. Across all open-market trades the lifetime net is −$157.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.49B across reported positions. The firm reports its address in Hellerup. 8 SEC filings were submitted jointly with Inozyme Pharma, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.49B
Companies
44
Total Filings
153
Lifetime Open-Market Net
-$157.03M
Filer Profile
Reported Address
TUBORG HAVNEVEJ 19HELLERUP 2900
Phone
(458) 824-8824
State of Incorporation
Denmark
Formerly Known As
Novo A/S (2007–2017)
Related Filers
Inozyme Pharma, Inc. — 8 joint filings, latest 2021-07-30
ANAPTYSBIO, INC — 6 joint filings, latest 2017-08-21
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| COAG | 10%+ Owner | 4,180,550 | $39.40 | $164.71M | $0 | 1 | 2026-05-06 |
| AVLN | 10%+ Owner | 3,327,734 | $33.57 | $111.71M | $10.00M | 1 | 2026-05-05 |
| MPLT | 10%+ Owner | 2,733,681 | $13.00 | $35.54M | $16.20M | 1 | 2025-10-30 |
| IO Biotech, Inc. (IOBT) Delisted | 10%+ Owner | 4,354,449 | $0.05 | $209.0K | $7.66M | 5 | 2024-07-26 |
| SPRB | 10%+ Owner | 34,000 | $53.70 | $1.83M | $738.2K | 6 | 2024-03-25 |
| MGX | 10%+ Owner | 100,000 | $1.16 | $116.0K | $13.03M | 1 | 2024-02-15 |
| Cyteir Therapeutics, Inc. (CYT) Delisted | 10%+ Owner | 3,522,136 | $3.02 | $10.64M | $1.24M | 9 | 2023-07-20 |
| IRON | 10%+ Owner | 1,090,772 | $70.06 | $76.42M | -$57.62M | 1 | 2023-06-28 |
| OnKure Therapeutics, Inc. (RPHM) Delisted | 10%+ Owner | 333,034 | $18.20 | $6.06M | $9.29M | 2 | 2023-06-23 |
| EWTX | 10%+ Owner | 6,071,703 | $44.40 | $269.58M | $15.00M | 2 | 2022-09-16 |
| BOLT | 10%+ Owner | 185,200 | $3.95 | $731.5K | $6.40M | 2 | 2022-07-15 |
| Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | 10%+ Owner | 2,162,290 | $10.50 | $22.70M | $7.48M | 2 | 2022-02-25 |
| Arcellx, Inc. (ACLX) Delisted | 10%+ Owner | 3,183,545 | $115.07 | $366.33M | $12.50M | 1 | 2022-02-09 |
| MINERVA SURGICAL INC (UTRS) Delisted | 10%+ Owner | 44,224 | $0.00 | $4 | $6.96M | 1 | 2021-10-27 |
| Verve Therapeutics, Inc. (VERV) Delisted | 10%+ Owner | 793,265 | $11.13 | $8.83M | $6.65M | 1 | 2021-06-22 |
| INGN | 10%+ Owner | 2,079,320 | $5.31 | $11.04M | -$129.87M | 5 | 2021-06-03 |
| Galera Therapeutics, Inc. (GRTX) Delisted | 10%+ Owner | 12,295 | $17.60 | $216.4K | -$4.24M | 3 | 2021-02-19 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 2,194,379 | $4.00 | $8.78M | -$1.88M | 2 | 2021-02-01 |
| Damora Therapeutics, Inc. (GLTO) Delisted | 10%+ Owner | 86,578 | $28.69 | $2.48M | $5.00M | 1 | 2020-11-04 |
| Eargo, Inc. (EAR) Delisted | 10%+ Owner | 44,354 | $2.57 | $114.0K | $2.70M | 1 | 2020-10-22 |
| ALGS | 10%+ Owner | 96,583 | $5.22 | $504.2K | $3.00M | 1 | 2020-10-22 |
| PRAX | 10%+ Owner | 162,805 | $334.58 | $54.47M | $0 | 1 | 2020-10-21 |
| HRMY | 10%+ Owner | 3,754,973 | $41.52 | $155.91M | $3.18M | 2 | 2020-09-04 |
| NKTX | 10%+ Owner | 2,793,865 | $2.91 | $8.13M | $10.00M | 1 | 2020-07-16 |
| CRVS | 10%+ Owner | 1,389,498 | $12.91 | $17.94M | $6.67M | 6 | 2020-07-09 |
| MIST | 10%+ Owner | 2,434,470 | $0.98 | $2.39M | $1.16M | 2 | 2019-11-27 |
| MIRM | 10%+ Owner | 1,870,147 | $98.22 | $183.69M | $8.62M | 1 | 2019-07-23 |
| Morphic Holding, Inc. (MORF) Delisted | 10%+ Owner | 1,978,779 | $56.99 | $112.77M | $10.00M | 1 | 2019-07-01 |
| Entasis Therapeutics Holdings Inc. (ETTX) Delisted | 10%+ Owner | 1,092,008 | $2.19 | $2.39M | $16.35M | 1 | 2018-10-01 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | 10%+ Owner | 1,726,481 | $27.00 | $46.61M | -$28.82M | 3 | 2017-10-12 |
| HTG MOLECULAR DIAGNOSTICS, INC (HTGM) Delisted | 10%+ Owner | 6,126 | $0.48 | $2.9K | $2.86M | 3 | 2017-08-25 |
| ANAB | 10%+ Owner | 1,936,604 | $53.87 | $104.32M | -$22.57M | 5 | 2017-08-21 |
| Apollo Endosurgery, Inc. (APEN) Delisted | 10%+ Owner | 1,301,842 | $10.00 | $13.02M | -$936.5K | 2 | 2017-07-26 |
| REATA PHARMACEUTICALS INC (RETA) Delisted | 10%+ Owner | 642,405 | $172.36 | $110.72M | -$1.53M | 6 | 2017-06-23 |
| IVERIC bio, Inc. (OPHT) Delisted | 10%+ Owner | 0 | — | — | -$163.30M | 6 | 2016-12-16 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 924,970 | — | — | $3.20M | 1 | 2016-11-02 |
| IRTC | 10%+ Owner | 2,124,448 | $111.43 | $236.73M | $1.70M | 1 | 2016-10-26 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | 10%+ Owner | 3,156,563 | — | — | $15.00M | 2 | 2016-09-13 |
| Tobira Therapeutics, Inc. (TBRA) Delisted | 10%+ Owner | 1,905,789 | — | — | $755.7K | 7 | 2016-07-13 |
| FLXN | 10%+ Owner | 2,247,431 | $24.62 | $55.33M | $14.41M | 3 | 2015-06-22 |
| NEVRO CORP (NVRO) Delisted | 10%+ Owner | 2,194,841 | $5.84 | $12.82M | $3.87M | 1 | 2014-11-13 |
| OTONOMY, INC. (OTIC) Delisted | 10%+ Owner | 2,175,025 | $0.08 | $167.5K | $2.99M | 2 | 2014-08-21 |
| AKBA | 10%+ Owner | 1,516,387 | $0.95 | $1.44M | $3.10M | 1 | 2014-03-26 |
| BIOMIMETIC THERAPEUTICS, INC. (BMTI) Delisted | 10%+ Owner | 4,720,065 | — | — | $26.02M | 33 | 2010-07-19 |
Recent Filings
153 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-30 | MPLT | Notice (144) | −1,600,000 | -$24.03M | EDGAR |
| 2026-05-06 | COAG | Conv (C) | +4,180,550 | $0 | EDGAR |
| 2026-05-05 | AVLN | Mixed | +3,883,289 | $10.00M | EDGAR |
| 2025-10-30 | MPLT | Mixed | +3,686,622 | $16.20M | EDGAR |
| 2024-09-11 | IO Biotech, Inc. (IOBT) Delisted | Notice (144) | −1,000,000 | -$844.0K | EDGAR |
| 2024-07-26 | IO Biotech, Inc. (IOBT) Delisted | Sell (S) | −75,000 | -$99.1K | EDGAR |
| 2024-07-25 | IO Biotech, Inc. (IOBT) Delisted | Notice (144) | −75,000 | -$101.2K | EDGAR |
| 2024-05-14 | IO Biotech, Inc. (IOBT) Delisted | Sell (S) | −658,809 | -$802.5K | EDGAR |
| 2024-05-10 | IO Biotech, Inc. (IOBT) Delisted | Notice (144) | −658,809 | -$988.2K | EDGAR |
| 2024-03-25 | SPRB | Sell (S) | −465,021 | -$351.0K | EDGAR |
Showing 1–10 of 153
Page 1 of 16
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.